BENEFIT Extension Study

Bayer

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

Study type: Observational

Funder types: Industry

Identifiers

NCT00544037

91713

311129 (Other Identifier)

Details and patient eligibility

About

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Enrollment: 283 patients

Sex: All

Ages: 23 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients randomized and treated at least once in study 304747

Exclusion criteria

• Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Trial design

283 participants in 1 patient group

Group 1

Treatment:

Drug: Interferon beta-1b (Betaseron, BAY86-5046)